Oseltamivir
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Oseltamivir: From Influenza to Pyelonephritis
One-Sentence Summary
Oseltamivir is a neuraminidase inhibitor antiviral, originally used to treat influenza. The TxGNN model predicts it may be effective for pyelonephritis (score 97.8%), but there are 0 clinical trials and 1 publication (a general review that does not support this use). This is a computational prediction only, with no clinical support.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Influenza (based on the literature in the Evidence Pack; SAHPRA indication text was not provided) |
| Predicted New Indication | Pyelonephritis |
| TxGNN Prediction Score | 97.85% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the Evidence Pack. Oseltamivir is known as a neuraminidase inhibitor that limits the release and spread of influenza virus, and its efficacy in influenza is established.
Pyelonephritis is a bacterial kidney infection, usually of the urinary tract. Neuraminidase inhibition has no plausible link to it. The only retrieved article is a narrative review of influenza in pregnancy, which does not address urinary infection at all.
The high TxGNN score most likely reflects proximity in the knowledge graph rather than a real pharmacological effect. Until independent evidence appears, this prediction should be treated as unsupported.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 26033556 | 2015 | Review | Presse Medicale | Narrative review of influenza in pregnancy (higher risk of pneumonia and hospitalisation). It does not address pyelonephritis or urinary infection. |
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. 54/20.2.8/0687 | Oseltamivir Adco 30 Mg | Capsule | Not stated in the data provided |
| Reg. No. 56/20.2.8/1086 | Ozetir | Suspension | Not stated in the data provided |
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The pyelonephritis prediction has no clinical trials, no supporting literature and no plausible mechanism. The score alone does not justify further investment.
To proceed, the following is needed:
- Any independent clinical or mechanistic evidence linking oseltamivir to urinary tract or kidney infection
- The SAHPRA Professional Information (indications, warnings, contraindications)
- Mechanism of action data from DrugBank
Note: Other predictions in this Evidence Pack are better supported. Pneumonia (rank 8) is the strongest, at evidence level L2 and “Proceed with Guardrails”. Its support is indirect, coming from influenza-related pneumonia. Staphylococcus aureus infection and streptococcal pneumonia are research questions at L4. They should be evaluated in separate reports.
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.